메뉴 건너뛰기




Volumn 20, Issue 6, 2013, Pages 494-500

Transplantation for myelodysplastic syndromes 2013

Author keywords

allogeneic haematopoietic cell transplantation; conditioning regimens; cytogenetics; hypomethylating agents; myelodysplastic syndromes; relapse

Indexed keywords

AZACITIDINE; FLUDARABINE; MIDOSTAURIN; MOLECULAR MARKER; QUIZARTINIB; TREOSULFAN;

EID: 84885400184     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328364f547     Document Type: Review
Times cited : (7)

References (54)
  • 1
    • 78649429727 scopus 로고    scopus 로고
    • Reduced mortality after allogeneic hematopoietic-cell transplantation
    • Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091-2101.
    • (2010) N Engl J Med , vol.363 , pp. 2091-2101
    • Gooley, T.A.1    Chien, J.W.2    Pergam, S.A.3
  • 2
    • 0030897009 scopus 로고    scopus 로고
    • International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 1998 Feb 1;91(3):1100]
    • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 1998 Feb 1;91(3):1100]. Blood 1997; 89:2079-2088.
    • (1997) Blood , vol.89 , pp. 2079-2088
    • Greenberg, P.1    Cox, C.2    Lebeau, M.M.3
  • 3
    • 84866621729 scopus 로고    scopus 로고
    • Revised international prognostic scoring system for myelodysplastic syndromes
    • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454-2465.
    • (2012) Blood , vol.120 , pp. 2454-2465
    • Greenberg, P.L.1    Tuechler, H.2    Schanz, J.3
  • 4
    • 80053186861 scopus 로고    scopus 로고
    • Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
    • Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011; 96:1433-1440.
    • (2011) Haematologica , vol.96 , pp. 1433-1440
    • Malcovati, L.1    Della Porta, M.G.2    Strupp, C.3
  • 5
    • 84865168155 scopus 로고    scopus 로고
    • Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
    • Deeg HJ, Scott BL, Fang M, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012; 120:1398-1408.
    • (2012) Blood , vol.120 , pp. 1398-1408
    • Deeg, H.J.1    Scott, B.L.2    Fang, M.3
  • 6
    • 54349092877 scopus 로고    scopus 로고
    • Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype
    • Breems DA, van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791-4797.
    • (2008) J Clin Oncol , vol.26 , pp. 4791-4797
    • Breems, D.A.1    Van Putten, W.L.2    De Greef, G.E.3
  • 7
    • 79751531643 scopus 로고    scopus 로고
    • Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognos-tically worse than an otherwise complex karyotype
    • Patnaik MM, Hanson CA, Hodnefield JM, et al. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognos-tically worse than an otherwise complex karyotype. Leukemia 2011; 25:266-270.
    • (2011) Leukemia , vol.25 , pp. 266-270
    • Patnaik, M.M.1    Hanson, C.A.2    Hodnefield, J.M.3
  • 8
    • 79959358531 scopus 로고    scopus 로고
    • Partial and total monosomal karyotypes in myelodysplastic syndromes: Comparative prognostic relevance among 421 patients
    • Belli CB, Bengio R, Aranguren PN, et al. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. Am J Hematol 2011; 86:540-545.
    • (2011) Am J Hematol , vol.86 , pp. 540-545
    • Belli, C.B.1    Bengio, R.2    Aranguren, P.N.3
  • 9
    • 84858830672 scopus 로고    scopus 로고
    • New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge
    • Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30:820-829.
    • (2012) J Clin Oncol , vol.30 , pp. 820-829
    • Schanz, J.1    Tuchler, H.2    Sole, F.3
  • 10
    • 84875758862 scopus 로고    scopus 로고
    • Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodys-plastic syndrome
    • Valcarcel D, Adema V, Sole F, et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodys-plastic syndrome. J Clin Oncol 2013; 31:916-922.
    • (2013) J Clin Oncol , vol.31 , pp. 916-922
    • Valcarcel, D.1    Adema, V.2    Sole, F.3
  • 11
    • 79959794787 scopus 로고    scopus 로고
    • Clinical effect of point mutations in myelodysplastic syndromes
    • Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364:2496-2506.
    • (2011) N Engl J Med , vol.364 , pp. 2496-2506
    • Bejar, R.1    Stevenson, K.2    Abdel-Wahab, O.3
  • 12
    • 40749135870 scopus 로고    scopus 로고
    • A prognostic score for patients with lower risk myelodysplastic syndrome
    • Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008; 22:538-543.
    • (2008) Leukemia , vol.22 , pp. 538-543
    • Garcia-Manero, G.1    Shan, J.2    Faderl, S.3
  • 13
    • 79960255863 scopus 로고    scopus 로고
    • Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
    • Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25:1153-1158.
    • (2011) Leukemia , vol.25 , pp. 1153-1158
    • Walter, M.J.1    Ding, L.2    Shen, D.3
  • 14
    • 80054010617 scopus 로고    scopus 로고
    • Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts
    • Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365:1384-1395.
    • (2011) N Engl J Med , vol.365 , pp. 1384-1395
    • Papaemmanuil, E.1    Cazzola, M.2    Boultwood, J.3
  • 15
    • 80053900941 scopus 로고    scopus 로고
    • Frequent pathway mutations of splicing machinery in myelodysplasia
    • Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64-69.
    • (2011) Nature , vol.478 , pp. 64-69
    • Yoshida, K.1    Sanada, M.2    Shiraishi, Y.3
  • 16
    • 84555192302 scopus 로고    scopus 로고
    • Recurrent mutations in the U2AF1 splicing & factor in myelodysplastic syndromes
    • Spliceosome mutations are the most frequent mutations inMDS and correlate with disease phenotype
    • Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing & factor in myelodysplastic syndromes. Nat Genet 2012; 44:53-57. Spliceosome mutations are the most frequent mutations inMDS and correlate with disease phenotype.
    • (2012) Nat Genet , vol.44 , pp. 53-57
    • Graubert, T.A.1    Shen, D.2    Ding, L.3
  • 17
    • 84866749552 scopus 로고    scopus 로고
    • Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes
    • Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30:3376-3382.
    • (2012) J Clin Oncol , vol.30 , pp. 3376-3382
    • Bejar, R.1    Stevenson, K.E.2    Caughey, B.A.3
  • 18
    • 0037105374 scopus 로고    scopus 로고
    • Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia
    • Sierra J, Pérez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100:1997-2004.
    • (2002) Blood , vol.100 , pp. 1997-2004
    • Sierra, J.1    Pérez, W.S.2    Rozman, C.3
  • 19
    • 58149196171 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: Importance of pretransplant disease burden
    • Warlick ED, Cioc A, DeFor T, et al. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009; 15:30-38.
    • (2009) Biol Blood Marrow Transplant , vol.15 , pp. 30-38
    • Warlick, E.D.1    Cioc, A.2    Defor, T.3
  • 20
    • 3142580475 scopus 로고    scopus 로고
    • A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome
    • Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104:579-585.
    • (2004) Blood , vol.104 , pp. 579-585
    • Cutler, C.S.1    Lee, S.J.2    Greenberg, P.3
  • 21
    • 33846953453 scopus 로고    scopus 로고
    • Myelodysplastic syndromes in patients younger than age 50
    • Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006; 24:5358-5365.
    • (2006) J Clin Oncol , vol.24 , pp. 5358-5365
    • Kuendgen, A.1    Strupp, C.2    Aivado, M.3
  • 22
    • 11244278531 scopus 로고    scopus 로고
    • Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome
    • Scott BL, Storer B, Loken M, et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005; 11:65-73.
    • (2005) Biol Blood Marrow Transplant , vol.11 , pp. 65-73
    • Scott, B.L.1    Storer, B.2    Loken, M.3
  • 23
    • 20144375580 scopus 로고    scopus 로고
    • Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome
    • Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005; 19:396-401.
    • (2005) Leukemia , vol.19 , pp. 396-401
    • Nakai, K.1    Kanda, Y.2    Fukuhara, S.3
  • 24
    • 33846924515 scopus 로고    scopus 로고
    • Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    • Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007; 109: 1395-1400.
    • (2007) Blood , vol.109 , pp. 1395-1400
    • Estey, E.1    De Lima, M.2    Tibes, R.3
  • 25
    • 84864018433 scopus 로고    scopus 로고
    • Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS
    • Gerds AT, Gooley TA, Estey EH, et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012; 18:1211-1218.
    • (2012) Biol Blood Marrow Transplant , vol.18 , pp. 1211-1218
    • Gerds, A.T.1    Gooley, T.A.2    Estey, E.H.3
  • 26
    • 84871752557 scopus 로고    scopus 로고
    • Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: A study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies
    • Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 2012; 30:4533-4540.
    • (2012) J Clin Oncol , vol.30 , pp. 4533-4540
    • Damaj, G.1    Duhamel, A.2    Robin, M.3
  • 27
    • 23944440464 scopus 로고    scopus 로고
    • Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT
    • Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912-2919.
    • (2005) Blood , vol.106 , pp. 2912-2919
    • Sorror, M.L.1    Maris, M.B.2    Storb, R.3
  • 28
    • 0032006125 scopus 로고    scopus 로고
    • Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
    • Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91:756-763.
    • (1998) Blood , vol.91 , pp. 756-763
    • Slavin, S.1    Nagler, A.2    Naparstek, E.3
  • 29
    • 33644967374 scopus 로고    scopus 로고
    • Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis
    • Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20:128-135.
    • (2006) Leukemia , vol.20 , pp. 128-135
    • Scott, B.L.1    Sandmaier, B.M.2    Storer, B.3
  • 30
    • 84879104114 scopus 로고    scopus 로고
    • Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: A report from EBMT
    • Martino R, de Wreede L, Fiocco M, et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant 2013; 48:761-770.
    • (2013) Bone Marrow Transplant , vol.48 , pp. 761-770
    • Martino, R.1    De Wreede, L.2    Fiocco, M.3
  • 31
    • 84857030601 scopus 로고    scopus 로고
    • Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
    • Luger SM, Ringdén O, Zhang M-J, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47:203-211.
    • (2012) Bone Marrow Transplant , vol.47 , pp. 203-211
    • Luger, S.M.1    Ringdén, O.2    Zhang, M.-J.3
  • 32
    • 79551688903 scopus 로고    scopus 로고
    • Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies
    • Nemecek ER, Guthrie KA, Sorror ML, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 2011; 17: 341-350.
    • (2011) Biol Blood Marrow Transplant , vol.17 , pp. 341-350
    • Nemecek, E.R.1    Guthrie, K.A.2    Sorror, M.L.3
  • 33
    • 0037103191 scopus 로고    scopus 로고
    • Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
    • Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100:1201-1207.
    • (2002) Blood , vol.100 , pp. 1201-1207
    • Deeg, H.J.1    Storer, B.2    Slattery, J.T.3
  • 34
    • 4644359708 scopus 로고    scopus 로고
    • Impact of HLA class i and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome
    • Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood 2004; 104:1923-1930.
    • (2004) Blood , vol.104 , pp. 1923-1930
    • Flomenberg, N.1    Baxter-Lowe, L.A.2    Confer, D.3
  • 35
    • 36048965258 scopus 로고    scopus 로고
    • Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors
    • Mielcarek M, Storer BE, Sandmaier BM, et al. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant 2007; 13:1499-1507.
    • (2007) Biol Blood Marrow Transplant , vol.13 , pp. 1499-1507
    • Mielcarek, M.1    Storer, B.E.2    Sandmaier, B.M.3
  • 36
    • 79960208605 scopus 로고    scopus 로고
    • Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation
    • Ho VT, Kim HT, Aldridge J, et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:1196-1204.
    • (2011) Biol Blood Marrow Transplant , vol.17 , pp. 1196-1204
    • Ho, V.T.1    Kim, H.T.2    Aldridge, J.3
  • 37
    • 84885413155 scopus 로고    scopus 로고
    • Comparison of outcomes after related and unrelated hematopoietic cell transplantation in adults with myelodysplas-tic syndromes: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR)
    • Epub ahead of print
    • Saber W, Cutler C, Nakamura R, et al. Comparison of outcomes after related and unrelated hematopoietic cell transplantation in adults with myelodysplas-tic syndromes: a report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood 2013. [Epub ahead of print]
    • (2013) Blood
    • Saber, W.1    Cutler, C.2    Nakamura, R.3
  • 38
    • 84878406500 scopus 로고    scopus 로고
    • Who is the better donor for older hematopoietic transplant recipients: An older-aged sibling or a young, matched unrelated volunteer?
    • Alousi AM, Le-Rademacher J, Saliba RM, et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood 2013; 121:2567-2573.
    • (2013) Blood , vol.121 , pp. 2567-2573
    • Alousi, A.M.1    Le-Rademacher, J.2    Saliba, R.M.3
  • 39
    • 10744229863 scopus 로고    scopus 로고
    • Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome
    • Ooi J, Iseki T, Takahashi S, et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101:4711-4713.
    • (2003) Blood , vol.101 , pp. 4711-4713
    • Ooi, J.1    Iseki, T.2    Takahashi, S.3
  • 40
    • 79951682984 scopus 로고    scopus 로고
    • Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes
    • Sato A, Ooi J, Takahashi S, et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant 2011; 46:257-261.
    • (2011) Bone Marrow Transplant , vol.46 , pp. 257-261
    • Sato, A.1    Ooi, J.2    Takahashi, S.3
  • 41
    • 84873558649 scopus 로고    scopus 로고
    • Haploidentical, unmani-pulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies
    • Di Bartolomeo P, Santarone S, De Angelis G, et al. Haploidentical, unmani-pulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121:849-857.
    • (2013) Blood , vol.121 , pp. 849-857
    • Di Bartolomeo, P.1    Santarone, S.2    De Angelis, G.3
  • 42
    • 20644470338 scopus 로고    scopus 로고
    • Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse
    • Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23:3447-3454.
    • (2005) J Clin Oncol , vol.23 , pp. 3447-3454
    • Aversa, F.1    Terenzi, A.2    Tabilio, A.3
  • 43
    • 84867592111 scopus 로고    scopus 로고
    • Peripheral-blood stem cells versus bone marrow from unrelated donors
    • Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367:1487-1496.
    • (2012) N Engl J Med , vol.367 , pp. 1487-1496
    • Anasetti, C.1    Logan, B.R.2    Lee, S.J.3
  • 44
    • 84867606906 scopus 로고    scopus 로고
    • Pursuing the goal of a donorfor everyone in need [Comment]
    • Appelbaum FR. Pursuing the goal of a donorfor everyone in need [Comment]. N Engl J Med 2012; 367:1555-1556.
    • (2012) N Engl J Med , vol.367 , pp. 1555-1556
    • Appelbaum, F.R.1
  • 45
    • 34548039048 scopus 로고    scopus 로고
    • Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: Similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
    • Chang CK, Storer BE, Scott BL, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110:1379-1387.
    • (2007) Blood , vol.110 , pp. 1379-1387
    • Chang, C.K.1    Storer, B.E.2    Scott, B.L.3
  • 46
    • 77950361766 scopus 로고    scopus 로고
    • Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia
    • Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115:1850-1857.
    • (2010) Blood , vol.115 , pp. 1850-1857
    • Litzow, M.R.1    Tarima, S.2    Perez, W.S.3
  • 47
    • 34548693215 scopus 로고    scopus 로고
    • Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hema-topoietic cell transplantation
    • Mielcarek M, Storer BE, Flowers MED, et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hema-topoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1160-1168.
    • (2007) Biol Blood Marrow Transplant , vol.13 , pp. 1160-1168
    • Mielcarek, M.1    Storer, B.E.2    Flowers, M.E.D.3
  • 48
    • 78649601394 scopus 로고    scopus 로고
    • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study
    • de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010; 116:5420-5431.
    • (2010) Cancer , vol.116 , pp. 5420-5431
    • De Lima, M.1    Giralt, S.2    Thall, P.F.3
  • 49
    • 84858800545 scopus 로고    scopus 로고
    • Treatment of recurrent or persistent AML/MDS after allogeneic hematopoietic cell transplantation with azacitidine [abstract]
    • abstr. 1288
    • Vaughn J, Storer B, Mielcarek M, et al. Treatment of recurrent or persistent AML/MDS after allogeneic hematopoietic cell transplantation with azacitidine [abstract]. Blood 2010; 116:551; abstr. 1288.
    • (2010) Blood , vol.116 , pp. 551
    • Vaughn, J.1    Storer, B.2    Mielcarek, M.3
  • 50
    • 84857999119 scopus 로고    scopus 로고
    • Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial
    • Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26:381-389.
    • (2012) Leukemia , vol.26 , pp. 381-389
    • Platzbecker, U.1    Wermke, M.2    Radke, J.3
  • 51
    • 0019970838 scopus 로고
    • Haematopoietic stimulators in the serum of patients with severe aplastic anaemia
    • Adams JA, Barrett AJ. Haematopoietic stimulators in the serum of patients with severe aplastic anaemia. Br J Haematol 1982; 52:327-335.
    • (1982) Br J Haematol , vol.52 , pp. 327-335
    • Adams, J.A.1    Barrett, A.J.2
  • 52
    • 24944495973 scopus 로고    scopus 로고
    • Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
    • Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
    • (2005) J Clin Oncol , vol.23 , pp. 5675-5687
    • Schmid, C.1    Schleuning, M.2    Ledderose, G.3
  • 53
    • 35748985559 scopus 로고    scopus 로고
    • Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation
    • Campregher PV, Gooley T, Scott BL, et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40:965-971.
    • (2007) Bone Marrow Transplant , vol.40 , pp. 965-971
    • Campregher, P.V.1    Gooley, T.2    Scott, B.L.3
  • 54
    • 80051992418 scopus 로고    scopus 로고
    • Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
    • Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29:3322-3327.
    • (2011) J Clin Oncol , vol.29 , pp. 3322-3327
    • Prebet, T.1    Gore, S.D.2    Esterni, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.